Napradiol (Diclofenac Sodium, Omeprazole)

Diclofenac Sodium and Omeprazole, the active ingredient in Napradiol, is a NSAID and proton pump inhibitor presented as an oral tablet for oral use. It provides analgesic and anti‑inflammatory effects while protecting the stomach lining in patients requiring NSAID therapy. GNH USA supplies Napradiol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Napradiol combines an NSAID with a proton‑pump inhibitor to manage pain‑related conditions and protect the gastrointestinal tract. - Osteoarthritis: reduces joint pain and inflammation, improving mobility. - Rheumatoid arthritis: alleviates chronic joint inflammation and pain. - Musculoskeletal pain: provides relief for acute or chronic muscle and tendon discomfort. - Gastro‑protective therapy for patients receiving NSAIDs: lowers the risk of ulceration and bleeding by suppressing gastric acid secretion.

Adverse reactions may occur with any medication and should be monitored by a healthcare professional.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding: severe stomach or intestinal lesions. - Liver enzyme elevation: signs of hepatic stress. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): extensive rash or blistering. - Renal impairment: reduced kidney function. - Cardiovascular events: increased risk of heart attack or stroke. - Anaphylaxis: rare, potentially life‑threatening allergic reaction.

Before initiating therapy, consider the following safety measures. - Renal function assessment: evaluate kidney health, especially in the elderly. - Hepatic monitoring: check liver enzymes periodically. - Lowest effective NSAID dose: use the minimal dose needed for symptom control. - History of ulcer disease: avoid in patients with active peptic ulcers. - Concomitant anticoagulant use: monitor bleeding risk closely. - Pregnancy and breastfeeding: safety not established; use only if clearly needed. - Store at ambient temperature: keep in the original pack, protect from moisture.

Drug‑drug interactions may alter efficacy or increase toxicity.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Lithium: increased serum lithium levels. - Methotrexate: reduced clearance, potential toxicity. - Cyclosporine: elevated cyclosporine concentrations.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., sertraline): modest increase in bleeding risk. - ACE inhibitors (e.g., enalapril): possible reduction in renal function. - Diuretics (e.g., furosemide): may affect kidney handling of NSAIDs. - Corticosteroids (e.g., prednisone): additive ulcer risk. - Antidiabetic agents (e.g., metformin): monitor blood glucose control.